ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™) [Yahoo! Finance]
HighReport
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™) [Yahoo! Finance]
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
HighReport
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
LowReport
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: